Progressive Care (RXMD) Proxy Filing summary

Executive summary

• The proxy filing details a proposed merger in which Progressive Care will merge with a wholly-owned subsidiary of NextPlat, making Progressive Care a wholly-owned subsidiary of NextPlat and issuing approximately 6.83 million shares of NextPlat common stock to Progressive Care stockholders, representing about 26.5% of NextPlat's post-merger common stock, subject to adjustments for options, warrants, and convertible securities.

• The merger is structured as a share exchange, with each Progressive Care common share converted into 1.4865 shares of NextPlat common stock, and Series B Preferred Stock converted into common stock before the exchange.

• The transaction is expected to close promptly after the special and annual meetings scheduled for September 13, 2024, pending shareholder approvals and satisfaction of closing conditions.

• The merger aims to provide Progressive Care with additional capital and access to U.S. capital markets, while streamlining compliance and reporting costs by consolidating public company operations.

Voting matters and shareholder proposals

• Shareholders are being asked to approve the Merger Agreement and the Business Combination; no other proposals will be voted on at the special meeting.

• Approval requires a majority of the voting power of Progressive Care's common and Series B preferred stock, voting as a single class.

• NextPlat and its affiliates, including key executives, already control over 53% of the voting power, making approval of the merger a practical certainty.

• Dissenting Progressive Care shareholders are entitled to appraisal rights under Delaware law if they do not vote in favor and follow required procedures.

Board of directors and corporate governance

• Upon closing, all Progressive Care directors will resign, and NextPlat's board will govern the combined company, which will have eight directors designated by NextPlat.

• Both companies formed special committees of independent directors to review, negotiate, and recommend the merger, given overlapping management and potential conflicts of interest.

• The combined company’s board will have a majority of independent directors, and standard board committees (audit, compensation, nominating/governance) will remain in place.